Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

Japanese patent issuances facilitate commercialization of MCC in Japan

26-Nov-2009 - Bioniche Life Sciences Inc. announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition. These patents have claims related to broad MCC compositions, pharmaceutical compositions and medicament compositions. The Japanese patent ...

Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well

20-Aug-2008 - Bioniche Life Sciences Inc. announced that its first Phase III clinical trial with a formulation of Mycobacterial Cell Wall-DNA Complex (MCC), trademarked Urocidin, for the treatment of bladder cancer, is progressing well. The Data Safety Monitoring Committee held its fifth scheduled meeting ...

Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial

12-Sep-2007 - Bioniche Life Sciences Inc. announced that an agreement has been reached with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure. This SPA agreement relates to the Company's pivotal Phase III study using its proprietary Mycobacterial Cell Wall-DNA ...

Bioniche Ships First Order of E. coli O157:H7 Cattle Vaccine

27-Aug-2007 - Bioniche Life Sciences Inc. announced that the first permit has been issued for its E. coli O157:H7 cattle vaccine, and that the first order of vaccine has been shipped to that customer. The vaccine will be used for the reduction of shedding of E. coli O157:H7 bacteria in cattle. Shed bacteria ...

Bioniche Completes Sale of Two Remaining Assets Associated with Irish Pharma Group

12-Dec-2006 - Bioniche Life Sciences Inc. announced that it has completed the sale of two of its remaining assets associated with Bioniche Pharma Holdings Limited, the entity which now holds the shares of Bioniche Pharma Group Limited. The Company reached an agreement last month with Bioniche Pharma Holdings ...

Bioniche Expands Patent Portfolio with Three New Patents

Patents cover human health technologies in U.S. and EU

06-Nov-2006 - Bioniche Life Sciences Inc. announced that it has been granted three new patents for its core proprietary Mycobacterial Cell Wall-DNA Complex (MCC) and the related oligonucleotides. The Company has been granted a patent in the U.S. entitled "Hyaluronic acid in the treatment of cancer" (U.S. ...

U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product

08-May-2006 - Bioniche Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's proprietary Mycobacterial Cell Wall-DNA Complex (MCC - trademarked Urocidin) for the treatment of non-muscle invasive bladder cancer in patients who are ...

Bioniche Granted First Major Composition Patent for Oligonucleotide Technology

15-Mar-2006 - Bioniche Life Sciences Inc. announced that it has been granted a European patent (EP1432450) covering the composition and use of a novel oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides", inventors Dr. Nigel C. ...

U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer

09-Feb-2006 - Bioniche Life Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the first of two Phase III clinical trials using the Company's proprietary Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of bladder ...

Bioniche Mycobacterial Cell Wall Extract (MCWE) Granted New Patent for Production Performance in Animals

27-May-2005 - Bioniche Life Sciences Inc. announced that it has had another new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology. More than 145 patents have now been issued or applied for related to this technology. The new patent relates to ...